Posted by Michael Wonder on 06 May 2021
Alberta, Canada, begins mandating switches from originator to biosimilar Humira
6 May 2021 - Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar versions as part of its Biosimilars Initiative.
Alberta, Canada has expanded its biosimilar switching program to include Humira (adalimumab) for all the originator indications except pediatric juvenile idiopathic arthritis, according to Alberta Blue Cross.
